Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study

Table 3 Pharmacokinetics of erlotinib after single-dose administration in combination with motesanib

		AUC_0—24		C_max
Dose Cohort	n	GLSM Ratio Week 3: Week 2^a (90% CI)	n	GLSM Ratio Week 3: Week 2^a (90% CI)
50 mg motesanib QD + 100 mg erlotinib QD + gemcitabine	7	0.49 (0.25-0.96)	7	0.65 (0.39-1.08)
100 mg motesanib QD + 100 mg erlotinib QD + gemcitabine	7	0.53 (0.25-1.11)	8	0.82 (0.49-1.37)
125 mg motesanib QD + 100 mg erlotinib QD + gemcitabine	9	0.91 (0.48-1.73)	10	0.73 (0.48-1.09)
75 mg motesanib BID + 100 mg erlotinib QD + gemcitabine	9	0.52 (0.37-0.74)	9	0.75 (0.54-1.05)
100 mg motesanib QD + 150 mg erlotinib QD	7	0.46 (0.34-0.60)	7	0.59 (0.41-0.84)
125 mg motesanib QD + 150 mg erlotinib QD	7	0.46 (0.19-1.13)	7	0.61 (0.50-0.73)

AUC_0—24 = area under the curve from time 0-24 h; BID = twice daily; C_max = peak plasma concentration; CI = confidence interval; GLSM = geometric least squares means; QD = once daily
^aWeek 3, erlotinib plus motesanib treatment; week 2, erlotinib treatment only.

ISSN: 1471-2407